"rationale","id","description","uuid:ID","name","instanceType","label"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","The main design for the study","7fff82a5-f3a4-4d69-ad89-8cc17afc4079","Study Design 1","StudyDesign",""
